tubulin inhibitor-6

Tubulin inhibitor 6 (iHAP1) is an inhibitor of tubulin and a potent inhibitor of multiple cancer cell lines.

PKA inhibitor fragment (6-22) amide Acetate is a synthetic peptide which selectively inhibits PKA activity by binding to its substrate site (IC50 < 2 nM).

Tubulin inhibitor 35 (Tubulin IN 35) is a potent dual inhibitor of topoisomerase I and microtubule protein polymerization with antitumor activity, inhibits migration and invasion of MGC-803 and RKO cell lines, interrupts the cell cycle and induces apoptosis.

Tubulin inhibitor 8 is an inhibitor of tubulin and various cancer cell lines and inhibits tubulin polymerisation and K562 cell growth with an IC50 of 0.73 μM and 14 nM respectively.

CDK4/6/1 Inhibitor (Crozbaciclib) is a type of CDK4/6 inhibitor (IC50s: 3 and 1 nM). CDK4/6 inhibitor is a class of compounds used for the treatment of some types of hormone receptor positive, HER2-negative breast cancer, which can block the process of breast cancer cell division and reproduction.

Tubulin inhibitor 24 is a potent inhibitor that can inhibit tubulin polymerization.

Tubulin inhibitor 32 is an orally active novel microtubule inhibitor with antiproliferative and antitumor activity, inhibits microtubule polymerization, induces apoptosis and cell cycle arrest in G2/M phase.

Carbonic anhydrase inhibitor 6 is a potent human carbonic anhydrase (hCA) inhibitor that inhibits hCA IX, hCA II, hCA XII, and hCA I. It is used in the study of diseases caused by abnormalities in carbonic anhydrase.

Protein kinase inhibitor 6 is a protein kinase inhibitor.

KRAS G12D inhibitor 6 is an efficacious compound that effectively inhibits KRAS G12D.

Tubulin polymerization-IN-6 (compound 5f) is a potent inhibitor of tubulin polymerization, with an IC50 of 1.09 μM. It not only inhibits cell migration and tube formation but also has anti-angiogenic properties. Additionally, Tubulin polymerization-IN-6 has been found to effectively hinder tumor growth in HT29 xenograft Balb/c nude mice [1].

Tubulin Inhibitor 37 (Compound 12) effectively impedes tubulin aggregation (IC50 = 1.3 µM) and demonstrates antiproliferative activity against human tumor cell lines, showing promise for cancer research [1].

Tubulin Inhibitor 38 (Compound 14), a tetrazole-based agent, demonstrates significant antiproliferative effects by inducing mitotic arrest and blocking the cell cycle at the G2/M phase, ultimately triggering apoptosis. Administered at 100 nM for 24 hours, it shows considerable cytotoxicity and selectivity within HeLa, MCF7, and U87 MG cell lines [1].

Tubulin Inhibitor 36 (Compound 10) serves as a potent novel inhibitor of tubulin polymerization, which consequently induces apoptosis in glioblastoma cells, reflected by an IC50 value of 1.5±0.1 μM. Exhibiting significant anti-mitotic activity, this compound demonstrates anti-tumor potential, particularly useful in glioblastoma multiforme (GBM) research [1].

Tubulin Inhibitor 33 is a dose-dependent inhibitor of tubulin polymerization, exhibiting an IC50 value of 9.05 μM. This compound demonstrates antitumor activity and induces apoptosis, making it useful for antitumor research [1].

Tubulin inhibitor 14 is a potent inhibitor of NQO2 (quinone oxidoreductase 2) with an IC50 of 1.0 μM which also inhibits tubulin polymerization and the formation of endothelial cell capillary-like tubes. Tubulin inhibitor 14 is a microtubule destabilizer with potential tumor-selective as well as anti-angiogenic and vascular-destructive properties [1].

Tubulin inhibitor 1 is an inhibitor of tubulin, inhibits tubulin polymerization, with potent anti-tumor activity, induces cellular apoptosis causes and cellular mitotic arrest in the G2/M phase.

Thrombin Inhibitor 6, with an IC 50 of 1 nM, acts as a potent anticoagulant by inhibiting thrombin.

Tubulin Inhibitor 28 (compound 2g), with an IC50 value of 1.2 μM, is a potent inhibitor of tubulin that exhibits significant anti-proliferative activity against MCF-7 cells [1].

RIP1 Kinase Inhibitor 6 is a potent and selective inhibitor of RIP1 kinase, demonstrating inhibitory activity with an IC50 of less than 100 nM in a human R1P1 kinase assay[1].

Mcl-1 inhibitor 6 is a potent, orally active chemical compound that selectively inhibits the myeloid cell leukemia 1 (Mcl-1) protein, with a high affinity (K d = 0.23 nM) and binding activity (K i = 0.02 μM). This compound exhibits exceptional selectivity over other members of the Bcl-2 family, including Bcl-2, Bcl2A1, Bcl-xL, and Bcl-w (K d >10 μM). Notably, Mcl-1 inhibitor 6 demonstrates strong antitumor activity.

Glyoxalase I inhibitor 6 (Compound 9j) is an inhibitor of glyoxalase I (Glo-I) with an IC50 value of 1.13 μM. This compound shows potential as an anticancer agent, demonstrating low toxicity [1].

Tubulin Inhibitor 21 (compound 6f), a hybrid based on chalcone and melatonin, exhibits potent tubulin inhibition properties. It demonstrates significant cytotoxic activity against SW480 cells (IC 50 =0.26 μM) while showing lesser effects on nonmalignant cells [1].

Tubulin inhibitor 12 (Hit 9) is a recently developed compound with potent inhibitory effects on tubulin (IC50 = 25.3 μM). This compound exhibits noteworthy anti-tumor and anti-proliferative activities, making it a promising candidate for the treatment of cancer [1].

Tubulin inhibitor 7 is an inhibitor of tubulin and a potent inhibitor of multiple cancer cell lines (tubulin polymerization (IC50: 0.52 μM), K562 cell growth (IC50: 11 nM)).

Tubulin inhibitor 26 (compound 3c) is an indazole derivative which is a potent tubulin inhibitor with noteworthy low nanomolar potency against HepG2, HCT116, SW620, HT29 and A549 cancer cell lines. Tubulin inhibitor 26 inhibits tumor cell in G2/M phase as well as induces cell apoptosis. Tubulin inhibitor 26 suppresses the growth of tumor in vivo without affecting the mice body weight [1].

Topoisomerase I inhibitor 6 (Compound 3) is a potent inhibitor of Topoisomerase I that traps the DNA-Top1 cleavage complex and has low cytotoxicity in non-cancerous cell lines. Research value.

IK1 inhibitor PA-6 (PA-6) is a selective and potent inhibitor of IK1 (KIR2.x ion-channel-carried inward rectifier current)(IC50 of 12-15 nM for human and mouse KIR2.x currents).

SIRT5 Inhibitor 6 is a potent, selective, and substrate-competitive inhibitor of SIRT5, exhibiting an IC50 of 3.0 μM, and demonstrates therapeutic potential for treating septic acute kidney injury (AKI) in vivo [1].

Chitin synthase inhibitor 6 (compound 9b) is a potent inhibitor of chitin synthase (CHS) (IC50: 0.21 mM). chitin synthase inhibitor 6 exhibits broad-spectrum antifungal effects against drug-resistant fungi and can be used to study fungal infections.

GSK-3β inhibitor 6 is a highly potent inhibitor of GSK-3β, with an IC50 value of 24.4 μM. It demonstrates significant enhancement of hepatocyte glucose uptake (38%). This compound holds great potential for studying various diseases including diabetes, inflammation, cancer, Alzheimer's disease, and bipolar disorder [1].

ITK inhibitor 6 is a selective and potent ITK inhibitor that acts on ITK (IC50: 4 nM), BTK (IC50: 133 nM), JAK3 (IC50: 320 nM), EGFR (IC50: 2360 nM), LCK (IC50: 155 nM). ITK inhibitor 6 inhibited the phosphorylation of PLCγ1 and ERK1/2 and showed anti-proliferative effect.

Tubulin inhibitor 23 is a potent Tubulin inhibitor (IC50: 4.8 μM). Tubulin inhibitor 23 exhibited antiangiogenic effects in a dose-dependent manner and could induce apoptosis. Tubulin inhibitor 23 has potential for leukemia research.

Tubulin inhibitor 20 (compound 1) shows the potential for the cancer research that is a potent tubulin inhibitor [1].

FGFR1 inhibitor-6 is a potent inhibitor of FGFR1 (IC50: 16.31 nM) with cytotoxic activity. fGFR1 inhibitor-6 is capable of blocking the cell cycle in pro-G1 and G2/M phases and inducing apoptosis.

Factor D inhibitor 6 is a potent, highly selective, orally active compound that specifically inhibits the activity of factor D (FD). It demonstrates an IC50 of 30 nM and a Kd of 6 nM. Notably, Factor D inhibitor 6 does not exhibit any inhibitory effects against factor B, classical and lectin complement-pathway activation, nor does it interfere with a broad array of receptors, ion channels, kinases, and proteases.

Tubulin Inhibitor 11 is a potent, orally active agent that inhibits tubulin by targeting the Colchicine binding site. It impedes tubulin polymerization, leading to mitotic blockade and apoptosis.

Tubulin inhibitor 19 (compound 9b) is a potent indole chalcone compound that exhibits strong inhibitory activity against tubulin. Its potential in cancer research makes it valuable for studying cancer diseases [1].

Tubulin Inhibitor 27 (DYT-1), a compound that inhibits tubulin polymerization with an IC50 of 25.6 μM, exhibits anti-angiogenesis and antitumor activities [1].

Tubulin inhibitor 29 (compound 3c) is a potent tubulin inhibitor that inhibits tubulin assembly and bounds in the colchicine site (IC 50 = 1.2 μM). Tubulin inhibitor 29 exhibits antiproliferative effects with an IC 50 value of 7.5 μM for MCF-7 cells. [1].

Tubulin inhibitor 17 (Compound 3b) is an inhibitor of tubulin polymerization (IC50 = 12.38 µM). Tubulin inhibitor 17 exhibits anticancer activities as well as induces cell apoptosis[1].

Tubulin Inhibitor 34 (compound b5), a potent anticancer agent, inhibits tubulin polymerization and induces G2/M arrest and apoptosis. The compound demonstrates significant antivascular and antitumor activity [1].

URAT1 inhibitor 6 (Compound 1h), with an IC50 of 35 nM for hURAT1, demonstrates 200-fold and 8-fold greater potency compared to Lesinurad and Benzbromarone, respectively. This compound is utilized in the study of inflammation [1].

Tuberculosis inhibitor 6 (compound 2c), a 3-methoxy-2-phenylimidazo[1,2-b]pyridazine derivative, is highly active against Mycobacterium tuberculosis (MIC 90 of ≤1.66 μM) and Mycobacterium marinum (MIC 90 of 2.65 μM) [1].

Tubulin inhibitor 16 is a potent tubulin inhibitor with antiproliferative activity. Tubulin inhibitor 16 exhibits cytotoxicity in HepG2 cells [1].

PI3K/mTOR Inhibitor-6 (Compound 19c) is a potent dual PI3K/mTOR inhibitor that is more stable than gedatolisib in artificial gastric fluid. 10 μM of PI3K/mTOR Inhibitor-6 significantly inhibits the PI3K/Akt/mTOR signalling pathway. PI3K/mTOR Inhibitor-6 has shown potential for research in cancer diseases.

Tubulin Inhibitor 31 is a potent compound with an inhibitory concentration (IC 50) of 4 µM, demonstrating significant anti-proliferative activity and the ability to inhibit HUVEC migration.

Microtubule inhibitor 6 (compound 17o) is a potent microtubule inhibitor. microtubule inhibitor 6 exhibited cytotoxicity against NCI-H460 cells, BxPC-3 cells, and HT-29 cells, with IC50 values of 14.0, 6.6, and 7.0 nM, respectively. Microtubule inhibitor 6 was able to effectively inhibit microtubule polymerization.

Tubulin Inhibitor 13 (E27) effectively inhibits tubulin polymerization with an IC50 of 16.1 μM. This compound also restricts cancer cell migration and invasion, promotes apoptosis, and exhibits notable anticancer activity [1].

Tubulin inhibitor 15 is a potent tubulin inhibitor with antiproliferative activity. Tubulin inhibitor 15 exhibits cytotoxicity in HepG2 cells [1].